| Literature DB >> 27321955 |
Jakob Hedegaard1, Philippe Lamy1, Iver Nordentoft1, Ferran Algaba2, Søren Høyer3, Benedicte Parm Ulhøi3, Søren Vang1, Thomas Reinert1, Gregers G Hermann4, Karin Mogensen4, Mathilde Borg Houlberg Thomsen1, Morten Muhlig Nielsen1, Mirari Marquez5, Ulrika Segersten6, Mattias Aine7, Mattias Höglund7, Karin Birkenkamp-Demtröder1, Niels Fristrup1, Michael Borre8, Arndt Hartmann9, Robert Stöhr9, Sven Wach10, Bastian Keck10, Anna Katharina Seitz11, Roman Nawroth11, Tobias Maurer11, Cane Tulic12, Tatjana Simic13, Kerstin Junker14, Marcus Horstmann15, Niels Harving16, Astrid Christine Petersen17, M Luz Calle18, Ewout W Steyerberg19, Willemien Beukers20, Kim E M van Kessel20, Jørgen Bjerggaard Jensen8, Jakob Skou Pedersen1, Per-Uno Malmström6, Núria Malats5, Francisco X Real21, Ellen C Zwarthoff20, Torben Falck Ørntoft1, Lars Dyrskjøt22.
Abstract
Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease with widely different outcomes. We performed a comprehensive transcriptional analysis of 460 early-stage urothelial carcinomas and showed that NMIBC can be subgrouped into three major classes with basal- and luminal-like characteristics and different clinical outcomes. Large differences in biological processes such as the cell cycle, epithelial-mesenchymal transition, and differentiation were observed. Analysis of transcript variants revealed frequent mutations in genes encoding proteins involved in chromatin organization and cytoskeletal functions. Furthermore, mutations in well-known cancer driver genes (e.g., TP53 and ERBB2) were primarily found in high-risk tumors, together with APOBEC-related mutational signatures. The identification of subclasses in NMIBC may offer better prognostication and treatment selection based on subclass assignment.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27321955 DOI： 10.1016/j.ccell.2016.05.004
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743